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Abstract
Background Issues of fertility and pregnancy place an extra
burden on females with primary immunodeficiencies. Patients
lack reliable information and providers lack guidelines to
counsel patients on these anxiety-provoking matters.
Objective To collate concerns and experiences related to fer-
tility and pregnancy from females with humoral immune
deficiencies.
Methods We conducted an internet-based survey of female
patients who self-identified as having a diagnosis of primary
humoral immune deficiency.
Results Responses from 490 women with common variable
immune deficiency and 100 with hypogammaglobulinemia
were evaluated. The reported fertility measure (% of women
who had had a birth) was statistically significantly lower as
compared to the general US population (70 % vs. 85 %,
p<0.0001) whereas the rates of spontaneous pregnancy loss
were comparable. This group reported a total of 966 pregnan-
cies; 72 % resulted in a live birth. A majority of the pregnan-
cies progressed with no incident and with continuation of their
IgG replacement therapy; 23 % reported an increase in IgG
dosing during pregnancy. Only 15 % of those reporting a first
pregnancy indicated that they had been diagnosed with im-
mune deficiency prior to their first pregnancy; these women
expressed concern regarding the effect of immune deficiency
on their fertility, pregnancy and decision to have children.
Conclusion With inherent limitations of self-reported re-
sponses to surveys, females with humoral immune deficien-
cies reported relatively good rates of fertility and pregnancies
ending in live births. Results of the survey will serve as peer
support for patients and inform counseling guidelines for
providers.
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Introduction
Primary immunodeficiency disorders (PI), such as common
v a r i a b l e i m m u n e d e f i c i e n c y ( C V I D ) a n d
hypogammaglobulinemia, affect a small but significant pro-
portion of the population. A 2006 prevalence study performed
estimates that approximately 1:1200 individuals in the U.S.
are diagnosed with a PI [1]. Although the exact prevalence of
CVID is not known, it is estimated that 1 in 25,000 to 1 in 50,
000 are affected in the US with equal numbers of males and
females [2, 3]. The etiology of these conditions is likely
multifaceted and polygenic with complex inheritance patterns
[4]. The most common manifestations are a history of infec-
tions that may be recurrent, persistent or with unusual organ-
isms. The diagnosis is made with a compatible history, a
decrease in serum immunoglobulin G (IgG) levels, and poor
or non-responsiveness to a vaccine challenge. Besides low
IgG levels, patients also have decreased levels of immuno-
globulins such as IgA and/or IgM. The diagnosis of these
conditions is often delayed [3, 5] and is made with a compat-
ible history and immunological testing. The management and
follow-up of these conditions, along with associated co-
morbidities such as chronic and recurrent infections, autoim-
mune phenomena, malignancy, and long-term sequelae on
different organ systems is complex and often requires specific
expertise [6, 7]. Immunoglobulin replacement therapy and
access to specialty care has resulted in increased numbers of
patients experiencing near normalcy with decreased infec-
tions, increased life expectancy and accomplishments of sig-
nificant life events such as education, employment, marriage
and motherhood [6–8]. The importance of recognition of the
immune deficiency prior to pregnancy and institution of IgG
replacement therapy before and during pregnancy cannot be
overemphasized as this not only protects the mother from
severe infections, but also provides transplacental IgG for
the fetus.
Issues of fertility and pregnancy place an extra burden on
the diagnosis, management, and long-term sequelae in fe-
males with CVID and hypogammaglobulinemia. Primary care
providers and specialists frequently encounter such questions
from patients and families, with some patients expressing
concern with regards to the level of knowledge their providers
had [9]. Often heard questions include: Will the immune
deficiency affect my fertility? What should I expect during
pregnancy? Can I continue my IgG replacement therapy
through pregnancy?
Currently, medical providers have to rely on their clinical
experience, professional peer support, and limited published
literature to counsel and manage patients with CVID and
hypogammaglobulinemia with regard to pregnancy. The
peer-reviewed scientific literature is limited to experience with
pregnancies in small numbers of patients, with few publica-
tions noted during the past decade [7, 10–24].
The question of fertility (or infertility) and pregnancy loss
in females with CVID and hypogammaglobulinemia is not
explicitly addressed in the literature. Anecdotally, there is no
specific evidence for infertility in individuals with CVID or
clear connections between the two; though secondary effects
(chronic sequelae) could lead to infertility [25]. Possible as-
sociations mediated through autoimmunity and possibly sen-
sitization to IgA are implied in one review [26] and with IgA
deficiency in celiac disease patients in one study [27].
A search of selected consumer health websites on the
internet for individuals with immune deficiencies such as
IDF Friends [28, 29], Daily Strength [30] [30] and primary
immunodeficiency support forum [31] reveals much appre-
hension, uncertainty, and lack of clarity with regard to im-
mune deficiency, fertility and pregnancy. Informational mate-
rials directed to patients are limited and have been noted from
non-profit foundation websites such as the Immune
Deficiency Foundation [29] and publications such as IG
Living [32]. More recently, several Facebook pages dedicated
to discussions and support for individuals with CVID have
been established for peer support and sharing.
With the objective of documenting the patient perspective
and experience, this study was undertaken to elicit responses
from adult females with CVID and hypogammaglobulinemia
to questions related to their experiences with fertility and
pregnancy. We used an internet-based survey to develop a
compendium of patient experiences that would inform and
improve the counseling of current and future patients with
regard to these important issues. The target audience for the
results includes patients/families with these conditions and
providers who care for them.
Methods
Setting
The Immune Deficiency Foundation (IDF) is a non-profit
national patient organization dedicated to improving the
diagnosis, treatment and quality of life of persons with
primary immunodeficiency diseases through advocacy,
education and research [29]. Patients and family members
are encouraged to register on the website to keep up to
date on matters related to immune deficiency disorders
and receive mailings from the foundation. The sign-up
page explicitly states, “By completing this form, you are
also playing a vital role in maintaining the largest data-
base of individuals whose lives are affected by primary
immunodeficiency diseases. Your information enables
IDF to perform valuable surveys that have been and will
continue to be instrumental in advancing the needs of the
primary immunodeficiency community.”
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Development and Administration of Internet-Based Survey
A detailed survey was developed with over 50 questions to
elicit responses in the following themes: demographics, his-
tory of primary immunodeficiency disorders (diagnosis and
management) in self and family members, detailed health
histories in self and first degree relatives for common and
uncommon conditions, perceptions and concerns regarding
fertility and pregnancy, impact of having an immune deficien-
cy on the decision to have children, outcomes of attempts to
get pregnant, and experiences/outcomes of any pregnancies.
(The full survey is available on request from the authors).
A brief introductory email with a clickable link to the URL
for the survey website embedded within was sent to email
addresses associated with females who voluntarily registered
on the IDF website as of March 2012. Two reminder emails
were sent to non-respondents during the month of March and
April 2012. Questions were sequenced based on responses so
as to not force respondents to answer questions that were not
relevant to them. Respondents had the option to start, save, and
return to complete the survey at their convenience. The survey
responses were anonymous and a link to the email addresses
was used only to send reminders to non-respondents.
All survey responses were collated and descriptive analyses
performed in aggregate using Microsoft Excel, Microsoft
Access (Microsoft Corporation, Seattle, Washington) and
SPSS Statistical Software (IBM Corporation, Armonk, New
York). The percentage of survey respondents that reported a
birth (fertility measure) was compared with US national statis-
tics [33] using Chi-square tests. Rates of pregnancy loss (spon-
taneous abortion or still birth) reported by survey respondents
were compared to US national statistics [34] using 1-sample
proportions test with continuity correction. The US national
statistics for birth rates are calculated as the number of births
divided by total population in the given year (s) [35]; thus the
numbers of births reported by survey respondents as a group
cannot be directly compared to US statistics. The metric report-
ed is the percentage of pregnancies resulting in live births [34].
Terminations of pregnancies reported by survey respondents
were compared to US national statistics [36]. Survey responses
from those who were diagnosed with PI at the time of their first
pregnancy were compared to those who were not diagnosed
before their first pregnancy using Fisher exact test.
This study was reviewed and approved by the Institutional
Review Board (IRB) of the University of Utah School of
Medicine.
Results
An introductory email with the URL link to the internet-based
survey embedded within was sent to 5945 known individual
email addresses registered in the IDF database as ofMarch 15,
2012. Of the nearly 1200 who started the survey on-line, 1101
females who were ≥18 years completed the survey. Assuming
that 50 % of the registrants in the database are female, the
response rate for this survey was 37 % (1101 of 2973). Of
these respondents, 490 reported a diagnosis of CVID and 100
reported hypogammaglobulinemia, resulting in a cohort of
590 females whose survey responses were analyzed for this
study.
Demographics and other Characteristics of Survey
Respondents
The average age of the 590 female survey respondents was
49 years (median 50 years, range 18–81 years). As shown in
Table 1, they had been diagnosed with either CVID or
hypogammaglobulinemia an average of 10.4 years prior to
this survey. Of the 92 % that indicated that they were on IgG
replacement therapy, the average duration of therapy was
9 years (median 7 years, range 1 to 57 years). The most
frequent route of IgG replacement therapy was by the intra-
venous route, administered every 4 weeks and at an average
dose of 36 g.
Medical co-Morbidities in Survey Respondents
and First-degree Relatives
The most frequent co-occurring conditions reported by fe-
males with CVID or hypogammaglobulinemia were sinusitis,
allergies, pneumonia/lung disorders, asthma, and arthritis
(Table 2). Cold sores and gallstones were also reported in a
significant minority. A number of conditions were reported to
be present at the 10 % or greater level in parents, sisters, and
brothers; prominent were allergies, sinusitis, pneumonia/lung
disorders, and other disorders such as high blood pressure,
thyroid and heart disease. Primary immunodeficiencies were
reported to occur in very few first-degree relatives
(Supplementary Table S1 for details on all conditions
reported).
Fertility, Pregnancy Loss and live Births Among Survey
Respondents
The fertility measure (% of women who had had a birth)
reported by CVID and hypogammaglobulinemia patients
was statistically significantly lower as compared to the general
US population (70 % vs. 85 %, p<0.0001). The rates of
spontaneous pregnancy loss (noted as spontaneous abortions
by survey respondents) for first and second pregnancies were
no greater than the reported national average [34].
Terminations of pregnancies were reported at a calculated rate
of 159 per 1000 live births for the first pregnancy (41/1000
and 68/1000 for second and third pregnancies). These are
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Table 1 Characteristics of 590 female survey respondents who self-
identified themselves as females with a diagnosis of either common
variable immune deficiency or hypogammaglobulinemia
Characteristics Details
All female
Self-reported diagnosis, N=590 (%)
-CVID 490 (83)
-Hypogammaglobulinemia 100 (17)
Age distribution of respondents (years) Average: 49
Range: 18 to 81
Median: 50
Geographic distribution All 50 US States, District
of Columbia and Puerto
Rico
Duration of condition from diagnosis,
in years, N=582
Average: 10.4
Range: Less than 1 to 57
Median: 7.1
Duration of IgG replacement therapy, in years,N=545 Average: 9
Range: Less than 1 to 47
Median: 7 years
Modality of IgG replacement therapy ever received, N=590 (%)
-Intravenous route 485 (82)
-Subcutaneous route 284 (48)
-Intramuscular route 38 (6)
-Intravenous and subcutaneous 226 (38)
-Subcutaneous and intramuscular 23 (4)
-Intravenous and intramuscular 35 (6)
-Intravenous, subcutaneous and intramuscular 22 (4)
-Never treated with IgG 19 (3)
Frequency of IgG replacement therapy
-Intravenous route, N=267, (%)
• Every week 11 (4)
• Every 2 weeks 20 (7)
• Every 3 weeks 61 (23)
• Every 4 weeks 161 (61)
• Every 5 weeks 1 (<1)
• Every 6 weeks 12 (4)
-Subcutaneous route, N=232 (%)
• Daily 1 (<1)
• Twice a week 2 (9)
• Three times a week 1 (4)
• Weekly 198 (85)
• Every 2 weeks 3 (1)
Dose of IgG received as replacement therapy
-Intravenous route (N=240) Average in grams
• Every week 34
• Every 2 weeks 32
• Every 3 weeks 40
• Every 4 weeks 36
• Every 5 weeks 25
• Every 6 weeks 28
-Subcutaneous route (N=218) Average in milliliters
• Daily 10
• Twice a week 40
• Three times a week 38
• Weekly 54
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noted to be lower than the US national abortion rate of 228 per
1000 live births reported for 2010 [36].
Nearly three-quarters of all respondents indicated that they
did not have difficulty getting pregnant. Similar proportions
(72 %) reported that they had ever been pregnant. Of those
who had a child with an immune disorder, 60 % indicated that
this did not have an impact on their decision to have more
children. Overall 72 % of the pregnancies reported by survey
respondents resulted in live births.
Impact of Being Diagnosed With PI on Outcomes
and Concerns of Fertility and Childbearing
As it is likely that being pregnant may bias responses to
questions regarding outcomes of subsequent pregnancies, we
analyzed the impact of being diagnosed with PI at the time of
the first pregnancy. Of the 385 women reporting a first preg-
nancy, 58 reported having had a diagnosis of CVID or
hypogammaglobulinemia before the first pregnancy
(Table 3). If responses from those who were pregnant during
the survey were excluded, there were no differences in out-
comes of the first pregnancy between these groups (p=0.8).
Rates of infections during the first pregnancy were compara-
ble between the two groups with respondents reporting sinus,
ear, urinary and less frequently other infections. Of those
whose PI was diagnosed at the time of the first pregnancy, a
majority (over 70 %) reported concern regarding their ability
to have children, the child developing an immune deficiency,
or the pregnancy endangering their health (p<0.001). Those
who did not have their PI diagnosed at the time of the first
pregnancy expressed little concern. More of those who were
diagnosed prior to their first pregnancy indicated concerns
regarding PI having an impact on their decision to have or
try to have children (p<0.001).
Outcomes of Pregnancies and Management of Immune
Deficiency During Pregnancy
The 590 survey respondents reported a total of 966 pregnan-
cies with 385 (65 %) reporting at least one pregnancy. The
survey allowed responses for up to 10 pregnancies. The ma-
jority reported three pregnancies (385 females reported at least
one pregnancy, 286 reported two, 153 reported three); with
fewer females reporting subsequent pregnancies (number of
females reporting fourth through tenth pregnancies respective-
ly: 67, 32, 14, 6, 4, 2, 1). Table 4 shows data for first, second
and third pregnancies.
Excluding the 10 respondents who indicated they were
pregnant during the survey, the overall live birth rate was
reported to be 72 %. Nineteen percent (186) reported sponta-
neous abortion/stillbirth, 7 % (65) reported pregnancy termi-
nation (reasons were not reported) and 1 % (9) reported an
ectopic pregnancy.
In reviewing responses for those reporting 1 through 5
pregnancies (Fig. 1), the average years since those pregnan-
cies was between 24 and 29 years ago. Fifteen percent report-
ed a diagnosis of PI prior to their first pregnancy; there was an
upward trend in those diagnosed with PI prior to subsequent
pregnancies (30 %). There was also an increasing trend in
their concern about losing the pregnancy (from 37 to 66 %)
from first to subsequent pregnancies. Conversely, concerns
regarding the pregnancy endangering their health and their
children getting PI were lower with subsequent pregnancies.
Of the 154 pregnancies in which the PI was diagnosed prior
to the pregnancy (16 % of all reported pregnancies), the
survey respondents indicated that an immunologist had seen
them during 106 (69 %) of the pregnancies. The women
reported that prior to a majority of these pregnancies (91 %),
they had been on IgG replacement therapy. Similarly, IgG
replacement therapy was continued in a majority of the preg-
nancies (86 %) with maintenance of the route of administra-
tion (90 %) and frequency (90 %). If a switch occurred, it was
from IV route to sub-cutaneous (reasons were not reported).
Of those who responded to the question, 23 % indicated that
they had an increase in the dose of IgG during their pregnancy
(presumably to maintain pace with the weight gain of preg-
nancy). Nearly all (208, 96 %) of the pregnancies were re-
ported to be uneventful with no serious side effects of IgG
therapy. The few patients who experienced side effects were
managed by slowing the intravenous IgG infusion rate. There
was no change in laboratory testing during 90 % (122 of 136)
of the pregnancies. With data available only for the first
pregnancy, 77 % of the pregnancies were reported to have
been free of serious infections.
With regard to mode of delivery, 20 % of the pregnancies
resulting in live births were by C-section (151 of 784 re-
sponses). Three females indicated that their immune deficien-
cy influenced the decision to be delivered by C-section. A
change to their IgG therapy (dosing and/or frequency) was
reported after the completion of 21 % of pregnancies (24 of
114 responses).
Discussion
Following the principle of “if all else fails, ask the patient,”we
present the first descriptive analyses of responses of females
with CVID and hypogammaglobulinemia to questions related
to fertility and pregnancy. Developing and deploying an
internet-based survey directed to self-registered members of
a non -profit foundation allowed us to capture responses on a
cohort of patients much larger than from studies involving
individual clinical immunology practices. With responses
from 590 females reporting a total of 966 pregnancies, the
self-reported fertility measure of this cohort of females was
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lower whereas spontaneous pregnancy loss for first and sec-
ond pregnancies was on par with the general US population.
Reported termination rates of pregnancies were lower as com-
pared with US rates. Overall, 72 % of reported pregnancies
resulted in a live birth; this compares favorably to that reported
for the US in 2008 (65 %) [34].
Overall, the results of this survey should be encouraging to
those females and their families who have recently been








How many years ago was this pregnancy? Average: 24.74 years Average: 27.42 years Average: 28.54 years
What was the outcome for this pregnancy? (ALL) Range: 0 to 63 years Range: 0 to 62 years Range: 1 to 59 years
Median: 24 years Median: 27 years Median: 28 years
N (%) N (%) N (%)
Live birth 270 (70) 222 (78) 103 (67)
Currently pregnant 6 (2) 2 (<1) 1 (<1)
Ectopic pregnancy 2 (1) 3 (1) 2 (1)
Spontaneous abortion/stillbirth 63 (16) 49 (17) 40 (26)
Terminated pregnancy 43 (11) 9 (3) 7 (5)
Did you go to an immunologist during this pregnancy?
(diagnosed patients)
N (%) N (%) N (%)
Yes 36 (69) 30 (70) 23 (72)
No 9 (17) 7 (16) 3 (9)
Did not have immunologist 7 (14) 6 (14) 6 (19)
Were you receiving IgG replacement therapy before this
pregnancy?
N (%) N (%) N (%)
Yes 42 (79) 35 (81) 25 (78)
No 11 (21) 18 (19) 7 (22)
Did you receive IgG replacement therapy during this
pregnancy?
N (%) N (%) N (%)
Yes 40 (77) 34 (79) 21 (66)
No 12 (23) 9 (21) 11 (34)
Did you continue your IgG replacement therapy during
the entire pregnancy?
N (%) N (%) N (%)
Yes 38 (95) 38 (95) 21 (100)
No 1 (3) 2 (5) 0 (0)
No answer 1 (3) 0 (0) 0 (0)
While you were pregnant did the number of grams of IgG
increase, decrease or stay the same?
N (%) N (%) N (%)
Increased 15 (40) 7 (18) 4 (19)
Decreased 1 (3) 0 (0) 0 (0)
Stayed the same 22 (58) 31 (82) 17 (81)
While pregnant did you receive IgG therapy more often,
less often or did it stay the same?
N (%) N (%) N (%)
More often 6 (16) 3 (8) 4 (19)
Less often 0 (0) 0 (0) 0 (0)
Stayed the same 32 (84) 35 (92) 17 (81)
Did you experience any serious side effect from your IgG
therapy during this pregnancy?
N (%) N (%) N (%)
Yes 3 (8) 2 (5) 2 (10)
No 35 (92) 35 (95) 19 (90)
Were there any changes to the PI testing you had done during
your pregnancy? (Diagnosed only)
N % N % N %
Yes 7 (14) 3 (7) 3 (10)
No 45 (86) 38 (93) 28 (90)
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diagnosed with either CVID or hypogammaglobulinemia.
With the caveat that some familial clustering occurs and the
genetics of CVID and hypogammaglobulinemia are not
completely known, it is likely safe to say that females with
these PI could and should consider pregnancy to be a normal
part of their lives. Significant concerns regarding fertility and
outcomes of pregnancy are noted, especially and predictably,
among those who were diagnosed with PI before their first
pregnancy. However, overall, females with CVID and
hypogammaglobulinemia report that they are able to get preg-
nant and successfully carry the pregnancy to term.
In considering the survey results and anecdotes from clin-
ical practice, fertility remains a major concern for patients and
providers. It is possible that the fertility reported by survey
respondents were biased by those who elected not to have
children due to their diagnosis of PI. The etiology and treat-
ment of infertility is complex. For patients with PI this likely
represents a combination of factors including changes associ-
ated with humoral immune deficiency, associated co-
morbidities such as autoimmune phenomena, and treatments
of those conditions. This area merits further study in terms of
epidemiology and mechanisms.
Whereas spontaneous pregnancy loss rates were on par
with the general US population, the reported pregnancy ter-
mination rates were much lower than US rates. The termina-
tion rate was reported to be higher for the first pregnancy as
compared to the second and third pregnancies. A multitude of
factors including medical, psychological, and social stressors
are likely involved in decisions to terminate pregnancies.
It was alarming, though not entirely surprising, to note that
only 15% of patients who reported a first pregnancy indicated
that they had been diagnosed with an immune deficiency at
the time of their pregnancy. Though this increased during
subsequent pregnancies (Fig. 1), this likely poses a risk of
unforeseen complications for both mother and infant. This
also underscores a continued need for increased awareness
and education with regard to immune deficiencies among
healthcare providers. Of those who were diagnosed with PI
prior to their pregnancy, nearly all continued their IgG re-
placement therapy with no major side effects. It was also
interesting to note that of those who had a diagnosis of
immune deficiency, the majority were under the care of a
clinical immunologist, which likely accounts for their con-
tinuing IgG replacement therapy.
It is important to note that nearly a quarter of those who
were on IgG replacement at the time of their pregnancy report-
ed an increase in IgG dose during that pregnancy. Anecdotally,
clinical immunologists have considered more frequent testing
of serum IgG levels to account for transplacental transfer,
increased dosing of IgG during pregnancy to keep up with
the weight gain and a ‘booster’ dose prior to delivery [19, 20,
25, 37]. Amatching re-adjustment based on weight in the post-
partum period has also been noted in clinical practice. Of
interest, there were very few changes in IgG frequency or route
of administration during and after pregnancy.
The demographics, natural history, routes/doses of IgG
replacement therapy, and co-morbidities in the survey respon-
dents and first-degree relatives mirror clinical experience and
knowledge recorded in the literature. Some conditions in
parents and siblings may reflect age- and gender-related diag-
noses such as high blood pressure and heart disease.
Diagnoses such as gall stones and cold sores that are anecdot-
ally less noted among females with CVID were reported in a
significant minority. It was encouraging to note the low num-
bers of immune deficiency disorders reported in first-degree
relatives. It is important to note that these disorders are often
diagnosed later in life and thus may not have been known to
the survey respondents (especially in younger relatives).
Fig. 1 Reported selected
concerns and outcomes of first
through fifth pregnancies of
females with common variable
immune deficiency and
hypogammaglobulinemia;
Results of 939 pregnancies
reported for these questions
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The overall positive population level results from this
cohort with regard to fertility and pregnancy should not de-
tract from the concerns and unfortunate experiences of indi-
vidual females who have experienced infertility or pregnancy
loss while dealing with the complications and sequelae of
immune deficiencies. Empathy and understanding are of par-
amount importance in supporting individuals with chronic
diseases through life events.
The self-reported nature of survey responses is a limitation
of all such research. Those choosing to participate in the survey
may have biased the tone of the responses. There are no data to
indicate whether surveys of patients with rare conditions are
any more reliable than surveys of patients in general. A per-
ception among IDF database registrants that the survey was
meant only for young women who are currently in their child-
bearing years may have resulted in lower response rates. Due
to differences in demographics and data collection methods,
there are inherent challenges in comparing and extrapolating
survey responses of a group of self-identified patients with
relatively rare conditions to US national statistics.
The survey did not specifically ask about delays in diag-
nosis that are often noted in immune deficiency patients [3] or
issues related to menarche and menopause. Details of infec-
tions experienced during pregnancies and reports of neonatal
sepsis were not specifically sought in this survey. Clinicians
have been concerned about the lack of sufficient antibody to
pathogens such as Group B Streptococci and E. coli in new-
borns of females with CVID. This merits further study.
Developing formal counseling guidelines based on the
results of this survey should be pursued with a broad cross-
section of patients, patient advocate groups, providers and
professional organizations. Future work should involve
follow-up surveys to further elucidate fertility issues, infec-
tions and IgG therapy in the peri-natal period including during
breastfeeding. There is also a need to understand trends and
changes in fertility/pregnancy among the population of fe-
males with immune deficiency disorders over time. A long-
term prospective data collection study design for those newly
diagnosed with immune deficiency and are pregnant would
serve to support results of serial cross-sectional surveys. It
would also be important to understand these issues as they
relate to male patients and male partners of female patients.
Conclusions
In a first of its kind descriptive analyses of responses to an
internet-based survey, 590 females with PI reported on nearly
a thousand pregnancies. It was encouraging to note that fe-
males with CVID and hypogammaglobulinemia reported rel-
atively good rates of fertility and successfully carrying preg-
nancies to term (live births). A majority of the females con-
tinued their IgG replacement therapy during their pregnancy
with no adverse events. Results of the survey will serve as
patient peer support. Furthermore, these results should form
the basis for improving counseling guidelines for these im-
portant and anxiety-provoking topics.
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